Skip to main content
letter
. 2022 May 3;8(2):00082-2022. doi: 10.1183/23120541.00082-2022

FIGURE 1.

FIGURE 1

Both patients with idiopathic pulmonary fibrosis (IPF) receiving antifibrotics and patients with IPF under no treatment had reduced levels of anti-SARS-CoV-2 antibodies after two doses of SARS-CoV-2 mRNA vaccine compared to the general population (Kruskal–Wallis test, p=0.002). *: p<0.05.